3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
2
Thoracic
1
Other solid neoplasm
1
Genitourinary
1
Endocrine
1
Dermatologic
1
Conditions
Triple Negative Breast Neoplasms
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Interventions
Docetaxel
33
Radiosurgery
23
Radiotherapy
21
Sunitinib
20
pembrolizumab
18
Gemcitabine
16
Cisplatin
16
Androgen Antagonists
15
Nivolumab
14
enzalutamide
13
Goserelin
13
Prednisone
12
Leuprolide
12
Blood Specimen Collection
12
Abiraterone Acetate
12
bicalutamide
11
aldesleukin
11
Surveys and Questionnaires
11
Cyclophosphamide
11
Gonadotropin-Releasing Hormone
10
Bevacizumab
10
Multiparametric Magnetic Resonance Imaging
9
Carboplatin
9
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
8
Triptorelin Pamoate
8
Radiotherapy, Intensity-Modulated
8
Filgrastim
8
Epirubicin
8
Chemotherapy, Adjuvant
8
Brachytherapy
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
IPI-549
×
Genitourinary
×
Clear all
NCT03961698
2023-08-14
MARIO-3
Infinity Pharmaceuticals, Inc.
Phase 2
Unknown
91 enrolled